Stay updated on Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial
Sign up to get notified when there's something new on the Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial page.

Latest updates to the Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe new screenshot shows a visual refresh of the Record History page with the same version entries and layout as the old screenshot. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check40 days agoChange Detected- Added a government funding status notice and operating details for the NIH Clinical Center, indicating possible delays and updated status references. - Updated software version from v3.1.0 to v3.2.0.SummaryDifference9%

- Check47 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now adds a new date (2025-09-17), indicates Results Posted, and introduces an updated Results section (Outcome Measures (Results) with 2025-08-28), while removing the earlier 2025-05-09 Results Submitted. Overall, the page shifts from a submission status to published results.SummaryDifference2%

- Check62 days agoChange DetectedUpdated to revision v3.0.2. The 'Back to Top' link was removed; there are no changes to core content, pricing, stock availability, or time slots.SummaryDifference0.5%

- Check69 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.5%

Stay in the know with updates to Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Favezelimab Combo vs Standard in Metastatic CRC Clinical Trial page.